10 completed, 3 recruiting, 3 terminated, 2 active not recruiting. 21 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 10, Recruiting 3, Terminated 3, Active not recruiting 2, Not yet recruiting 2, Unknown 1 |
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1 |
Follow Giant Cell Tumors: new trials by email Literature Review of Giant Cell Tumors trials Research Report on Giant Cell Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor Pimicotinib, Tumor resection surgery - Tenosynovial Giant Cell Tumor, Diffuse | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 84 | 2027-10-01 | 2026-07-16 |
| A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT DCC-3014 - Tenosynovial Giant Cell Tumor | Phase 2 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 18 | 2026-10-31 | 2026-09-22 |
| Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) Pimicotinib - Tenosynovial Giant Cell Tumor | Phase 2 | Recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 20 | 2026-03-26 | 2026-10-23 |
| Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study ICG (Indocyanine Green) - Giant Cell Tumor of Bone | Phase 1 / Phase 2 | Recruiting | Tang Xiaodong | 45 | 2024-08-23 | 2024-10-18 |
| Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage 4mg ZOL loaded gentamicin PMMA, gentamicin PMMA - Giant Cell Tumor of Bone | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 153 | 2023-03-01 | 2023-03-15 |
| A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT AMB-05X - Pigmented Villonodular Synovitis, TGCT | Phase 2 | Completed | AmMax Bio, Inc. | 20 | 2023-01-26 | 2024-07-05 |
| A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 2 | Terminated | AmMax Bio, Inc. | 4 | 2021-09-16 | 2024-05-24 |
| An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS) | Phase 2 | Completed | AmMax Bio, Inc. | 11 | 2021-05-25 | 2024-06-27 |
| A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 2 | Completed | Daiichi Sankyo Co., Ltd. | 9 | 2021-03-15 | 2026-06-24 |
| Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone Dietary Supplement: Calcium/Vitamin D - Giant Cell Tumor of Bone | Phase 1 / Phase 2 | Unknown | Shanghai JMT-Bio Inc. | 139 | 2019-10-10 | 2022-10-14 |
| Reduced Dose-density of Denosumab for Unresectable GCTB Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] - Bone Giant Cell Tumor | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 2 | 2019-09-26 | 2021-01-06 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-05-22 |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Vimseltinib - Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 120 | 2017-02-16 | 2026-06-25 |
| Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor FPA008 - Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor | Phase 1 / Phase 2 | Completed | Five Prime Therapeutics, Inc. | 66 | 2015-06-01 | 2021-08-31 |
| MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) MCS110, Placebo - Pigmented Villonodular Synovitis, PVNS | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2012-04-23 | 2021-01-05 |
| Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Tasigna - Pigmented Villonodular Synovitis | Phase 2 | Completed | Centre Leon Berard | 50 | 2010-12-01 | 2013-04-16 |
| Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor nilotinib - Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor | Phase 2 | Completed | Andrew J. Wagner, MD, PhD | 17 | 2010-09-01 | 2026-02-20 |
| Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) Zoledronic acid - Giant Cell Tumor of Bone, Osteoclastoma | Phase 2 | Terminated | Leiden University Medical Center | 15 | 2008-12-01 | 2016-01-26 |
| Study of Denosumab in Subjects With Giant Cell Tumor of Bone Denosumab - Cancer, Giant Cell Tumors | Phase 2 | Completed | Amgen | 535 | 2008-09-09 | 2022-09-22 |
| Trial of Dasatinib in Advanced Sarcomas Dasatinib - Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 366 | 2007-05-01 | 2018-11-23 |
Showing 20 of 21. Sign in to see all of them.
Giant Cell Tumor of Tendon Sheath (10) · Synovitis, Pigmented Villonodular (10) · Giant Cell Tumor of Bone (9) · Sarcoma (2) · Bone Neoplasms (1) · Chondrosarcoma (1) · Chordoma (1) · Gastrointestinal Stromal Tumors (1) · Hemangiopericytoma (1) · Histiocytoma, Malignant Fibrous (1) · Neoplasms (1) · Neurofibrosarcoma (1) · Osteosarcoma (1) · Ovarian Neoplasms (1)
Neoplasms by Histologic Type (21) · Neoplasms, Connective Tissue (21) · Neoplasms, Connective and Soft Tissue (21) · Neoplasms (20) · Musculoskeletal Diseases (13) · Joint Diseases (12) · Muscular Diseases (12) · Synovitis (12) · Tendinopathy (12) · Neoplasms, Bone Tissue (9) · Giant Cell Tumor of Tendon Sheath (2) · Neoplasms, Fibrous Tissue (2) · Adnexal Diseases (1) · Bone Diseases (1)
Denosumab (3) · Vitamin D (2) · nilotinib (2) · CTLA-4 Antigen (1) · Calcium (1) · Cyclophosphamide (1) · Dasatinib (1) · Indocyanine Green (1) · Ipilimumab (1) · Nivolumab (1) · Zoledronic Acid (1) · aldesleukin (1) · cabiralizumab (1) · fludarabine (1) · gentamicin-polymethylmethacrylate bead (1)
AmMax Bio, Inc. (3) · Amgen (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Andrew J. Wagner, MD, PhD (1) · Centre Leon Berard (1) · Daiichi Sankyo Co., Ltd. (1) · Deciphera Pharmaceuticals, LLC (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Five Prime Therapeutics, Inc. (1) · Leiden University Medical Center (1) · M.D. Anderson Cancer Center (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Novartis Pharmaceuticals (1) · Ono Pharmaceutical Co., Ltd. (1) · Sarcoma Alliance for Research through Collaboration (1)
United States (9) · Netherlands (8) · Poland (6) · United Kingdom (5) · China (4) · France (4) · Italy (4) · Australia (3) · Japan (3) · Spain (3) · Canada (2) · Ukraine (2) · Austria (1) · Belgium (1) · Germany (1)
Dorothy Nguyen, MD (3) · A H Taminiau, MD PhD (1) · Amir A Jazaeri (1) · Andrew J. Wagner, MD, PhD (1) · Emanuela Palmerini (1) · H Gelderblom, MD PhD (1) · Hans Gelderblom (1) · J R Kroep, MD PhD (1) · Jean Yves Blay, PR (1) · Maitreyi Sharma, MD (1) · N A Hamdy, MD PhD (1)
PMID 25684041, PMID 29211870, PMID 29571946, PMID 30231890, PMID 31040253, PMID 33482769, PMID 35932628, PMID 39500883, PMID 41292259
2018 (1)